Novonesis stock (DK0060336014): Kepler Cheuvreux upgrades to Buy

Novonesis stock received a positive analyst update as Kepler Cheuvreux upgraded its rating to Buy from Hold and lifted the price target to 460 Danish kroner from a previous level. The move, announced on Wednesday, reflects confidence in the company's biosolutions platform, including enzymes and microbes that enable sustainable production processes, according to ad-hoc-news.de as of recent trading.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Novonesis: core business model

Novonesis develops and supplies biological solutions such as enzymes and microbes that replace traditional chemical processes in industries like food production, agriculture, and household care. The company, formed from the 2024 merger of Novozymes and Chr. Hansen, focuses on sustainability by enabling more efficient and eco-friendly manufacturing. Its biosolutions help customers reduce energy use, water consumption, and waste, positioning Novonesis as a leader in the bioeconomy.

Headquartered in Denmark, Novonesis operates globally with production sites and R&D centers supporting innovation in high-value enzymes for applications ranging from laundry detergents to animal feed. The business model emphasizes long-term partnerships with major industrial clients, recurring revenue from enzyme sales, and growth through R&D investments exceeding 15% of sales annually, as reported in recent financial updates on the company website.

Main revenue and product drivers for Novonesis

Key revenue streams for Novonesis come from its Food, Nutrition & Health division, which includes enzymes for baking, dairy, and beverages, alongside Household Care enzymes for detergents. The Agriculture & Bioenergy segment drives growth via microbial solutions for animal nutrition and biofuel production. In 2025 full-year results published earlier this year, biosolutions sales grew in double digits, fueled by demand for sustainable alternatives amid global decarbonization efforts.

Product innovation remains central, with recent launches targeting plant-based foods and precision fermentation. These drivers provide exposure to megatrends like sustainability and food security, appealing to US investors tracking biotech firms with ties to the US agriculture and consumer goods sectors.

Industry trends and competitive position

The biosolutions industry is expanding rapidly, driven by regulatory pressures for greener production and consumer demand for sustainable products. Novonesis holds a leading position with a diverse portfolio and strong IP moat from decades of enzyme engineering expertise. Competitors include DuPont and DSM, but Novonesis differentiates through its end-to-end bioscience platform post-merger.

Why Novonesis matters for US investors

Novonesis offers US investors indirect exposure to Europe's biotech innovation hub via its Nasdaq Copenhagen listing and unsponsored ADR (NZM) traded OTC in the US. The company's solutions support major US firms in food and agribusiness, benefiting from American market demand for bio-based ingredients amid farm bill discussions and ESG investing trends.

Conclusion

The Kepler Cheuvreux upgrade to Buy highlights analyst optimism for Novonesis' growth in sustainable biosolutions, amid a favorable industry backdrop. With strong revenue drivers in food and agriculture, the company maintains relevance for global portfolios. Investors should monitor upcoming quarterly results and R&D pipeline updates for further developments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.